Mold-Tek Technologies Ltd
MOLDTECHMold-Tek Technologies Ltd is strength at full price. The numbers are improving — and a P/E at the 83rd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 83rd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (5 weeks in) while the P/E sits at the 83rd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +1,223.5% year on year, and 144% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Mold-Tek Technologies Ltd trades at ₹193, in a confirmed uptrend and 5 weeks into that stage. That is +24.5% against its own 200-day average. It sits at 81% of a 52-week range of ₹125 to ₹209. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹193 it trades +24.5% versus its 200-day average and sits at 81% of its 52-week range (₹125–₹209).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +43% while the NIFTY 500 moved −1% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Mold-Tek Technologies Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: EARLY_EXPANSION. Our fortnightly research layers last read it on 22 August 2026.
Our read, 22 August 2026. Earnings turnaround off cyclical trough driven by the elimination of automotive division losses, expanding US civil backlog, and high-margin utility substation design.
From the numbers. Mold-Tek sits in early operating expansion following a sharp margin trough across late FY25 and FY26. Operating margin has recovered from negative 10.17% in March 2025 to 19.92% in June 2026. While trailing valuation…
From the price. Price stage 2, week 5 — above its 200-day line, relative strength rising.
From the research. Earnings turnaround off cyclical trough driven by the elimination of automotive division losses, expanding US civil backlog, and high-margin utility substation design.
🚨 Where they disagree. Mold-Tek sits in early operating expansion following a sharp margin trough across late FY25 and FY26. Operating margin has recovered from negative 10.17% in March 2025 to 19.92% in June 2026. While trailing valuation appears elevated at 36.15x PE (85th percentile), this is an artifact of depressed trailing twelve-month earnings. Normalizing operating margin to the mid-cycle baseline of 18.4% reduces the valuation to 18.5x normalized PE, placing it in the 34th percentile of 10-year history and confirming early-cycle attractiveness.
What is proven. Earnings turnaround off cyclical trough driven by the elimination of automotive division losses, expanding US civil backlog, and high-margin utility substation design.
What is not proven yet. Failure of quarterly operating margin to sustain above 15% across Q2 and Q3 FY27, or civil work-on-hand contracting below $3.5 million, indicating that Q1 FY27 operating leverage was transient or that Berryl integration is creating prolonged cash leakage.
🚨 What would change our mind. Failure of quarterly operating margin to sustain above 15% across Q2 and Q3 FY27, or civil work-on-hand contracting below $3.5 million, indicating that Q1 FY27 operating leverage was transient or that Berryl integration is creating prolonged cash leakage.
Layer 1 read, 22 August 2026 — KEEP. A loss-making division was cut and the profit came straight back — but only one clean quarter proves it. Mold-Tek was losing 7 to 8 crore a year in a car-engineering unit that kept its staff after its main customer's work dried up. Management cut that team from 160 people to about 60, and the effect is immediate: the June quarter earned 11.86 crore of operating profit on 59.54 crore of sales, a 19.92% margin, against MINUS 10% fifteen months earlier. The order book supports it too — US civil work in hand rose from $2.5 million to $5.0 million and the mix is shifting from $25-30 an hour drafting to $70-100 an hour design work. Two cautions keep this from top billing: the quarter immediately before this one made only a 1.86% margin, so one good quarter is not yet a trend; and money owed by…
What would change Layer 1’s mind. Quarterly operating margin failing to hold above 15% across Q2 and Q3 FY27 would prove the June quarter was the spike the flag says it might be — and given the Mar 2026 print of 1.86%, that is a live possibility rather than a formality. Equally, debtor days going past 90 in the FY27 filings with operating cash flow turning negative would confirm the growth is being bought with credit rather than earned, which is the open red flag I could not close from the call.
Layer 2 read, 22 August 2026 — ADVANCE. A permanent cost cut meets a supply-tightening sector, but receivables still need proof. Mold-Tek printed ₹11.86 Cr of operating profit at a 19.92% margin, and management says the Body-in-White team cut removed a recurring annual loss. Outside the company, the sector timeline is ALIGNED and supports selective deployment, while the capital-cycle block reads IDEAL_TROUGH_SETUP; the advance remains conditional because cash fell as debtor days rose.
What would change Layer 2’s mind. Flip to BENCH if Q2 or Q3 FY27 operating margin falls below 15% or current debtor days stay above the FY26 level while operating cash fails to recover; that would show the cost-cut gain is being consumed by collection stress.
Layer 3 read, 22 August 2026 — BENCH. A real cost cut is offset by a material hedge loss and a management team that keeps moving targets. An almost INR 4 crore currency-hedge loss aligns with Timeline R5 and remains material after hedge coverage was reduced. Management removed the recurring automotive loss, but guidance moved while Berryl's outlook fell to around 8% margin after key-design departures, so this P2 is not ready for capital.
What would change Layer 3’s mind. A Q3 FY27 filing showing group margin above 15%, Berryl at break-even or better, and no further key-design departures would flip BENCH to DEPLOY.
The test written in advance. Failure of quarterly operating margin to sustain above 15% across Q2 and Q3 FY27, or civil work-on-hand contracting below $3.5 million, indicating that Q1 FY27 operating leverage was transient or that Berryl integration is creating prolonged cash leakage. — the thesis as written as stated by the next result.
The test written in advance. Berryl Integration Friction and Margin Outlook Reduction — Berryl Integration Friction and Margin Outlook Reduction by the next result.
The test written in advance. Working Capital Elongation and Receivable Collection Cycles — Working Capital Elongation and Receivable Collection Cycles Debtor days exceeding 90 days in FY27 annual filings or operating cash flow turning negative. by the next result.
What the company does. Operating profit rebounded to ₹11.86 Cr with operating margin reaching 19.92% in Q1 FY27 as the ₹7-8 Cr annual automotive drain was eliminated through staff downsizing from 160 to 50. US civil engineering work-on-hand reached $4.5 million with higher-margin structural design commanding 3-4x higher billing rates of $70-100 per hour versus $25-30 per hour for detailing. Normalized PE of 18.5x at mid-cycle 18.4% operating margins offers meaningful margin of safety against the trailing multiple, supported by cumulative 3-year cash flow conversion of 1.44x.
🚨 What the surface reading misses. The surface reading is: PAT expanded 1223.5% YoY, which might read as an unrepeatable single-quarter optical spike. The research reads it further: The optical percentage is magnified by the depressed base quarter (Q1 FY26 PAT of ₹0.68 Cr), but the absolute operating profit of ₹11.86 Cr is backed by the permanent elimination of ₹7-8 Cr in annual automotive division losses and core civil volume growth.
🚨 What the surface reading misses. The surface reading is: Operating cash flow conversion of 1.44x indicates high-quality cash earnings. The research reads it further: Operating cash flow tracks ahead of reported net profit due to non-cash depreciation add-backs and disciplined working capital control across the core detailing business.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Mold-Tek Technologies Ltd reported ₹59.5 Cr of revenue in the Jun 26 quarter, +78.9% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 13.1% a year. The last full year, FY26, came in at ₹182 Cr. The last four reported quarters add to ₹208 Cr.
FY26 revenue came in at ₹182 Cr (+24.7% on the year), capping 10 years at 13.1% compound. The latest quarter (Jun 26) printed ₹59.5 Cr, +78.9% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +53.7% growth against the decade's 13.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +48.7% over the last 4 quarters against +12.8%/yr over the last 8 — accelerating; TTM profit +140.3% vs −17.0%/yr — accelerating.
FY26-Q4. revenue ₹55 Cr and profit ₹2 Cr as reported.
FY27-Q1. revenue ₹60 Cr and profit ₹9 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Mold-Tek Technologies Ltd's operating margin is 19.9% in the Jun 26 quarter, +18.5 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 6.0% to 29.0%. The current quarter sits inside that band.
Why this happened. Mold-Tek is executing a value chain climb by transitioning from standard structural steel detailing ($25-30 per hour) to connection and structural design ($70-80 per hour India delivery, $100+ per hour for US Professional Engineer stamped work). With 4 certified Professional Engineers across India and the US, increasing design contribution expands gross margins without proportional headcount growth.
The latest quarter's operating margin is 19.9%, +18.5 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 6.0%–29.0%.
Why the margin moved: operating margin went +18.5 pp year on year while gross margin went +0.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
FY26-Q4. revenue ₹55 Cr and profit ₹2 Cr as reported.
FY27-Q1. revenue ₹60 Cr and profit ₹9 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Mold-Tek Technologies Ltd earned ₹9.0 Cr of net profit in the Jun 26 quarter, +1,223.5% year on year. Full-year FY26 profit was ₹10.0 Cr. The 10-year compound rate is 5.2%. That is 15.1% of the quarter's revenue. The same quarter a year earlier earned ₹0.7 Cr. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹9.0 Cr, +1,223.5% year on year. On the full year, FY26 printed ₹10.0 Cr (−16.7%), and the 10-year compound rate is 5.2%.
Why profit moved: revenue contributed +78.9% and the margin +18.5 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +594.8% vs revenue +53.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q4. revenue ₹55 Cr and profit ₹2 Cr as reported.
FY27-Q1. revenue ₹60 Cr and profit ₹9 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 144% of Mold-Tek Technologies Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹15.0 Cr of operating cash against ₹10.0 Cr of profit. After ₹25.0 Cr of capital spending, ₹−10.0 Cr was left as free cash.
FY26: operating cash of ₹15.0 Cr against reported profit of ₹10.0 Cr, leaving free cash of ₹−10.0 Cr after ₹25.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 144% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 144%: the cash cycle stretched 12 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Mold-Tek Technologies Ltd's cash conversion cycle runs 84 days in FY26, up from 72 days in FY21. Capital spending ran ₹37.0 Cr over the last 3 years. At FY26 sales of ₹182 Cr each day of that cycle holds about ₹0.5 Cr, so roughly ₹42.0 Cr sits inside the business at any moment.
Why this happened. Surging US power demand for data center connections is driving orders for transmission lines, distribution poles, and substations. Mold-Tek expanded its poles and towers team to over 80 engineers and secured a $1 million annualized master service agreement with a leading US power distribution entity, transforming mechanical services from a drag into a profitable growth segment.
FY26: debtors at 84 days (an asset-light business — no inventory to speak of) — for a full cycle of 84 days, looser than FY21's 72.
In money terms: at FY26 sales of ₹182 Cr, each day of the cycle holds about ₹0.5 Cr — so the 84-day loop keeps roughly ₹42.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹37.0 Cr over the last 3 fiscal years against ₹19.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Mold-Tek Technologies Ltd earns a ROCE of 10% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 5.5% net margin on 1.06× asset turns.
FY26 ROCE is 10%.
Why the return is what it is — the wiring (FY26): 5.5% net margin × 1.06× asset turns × 1.34× balance-sheet leverage ≈ 7.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Mold-Tek Technologies Ltd carries ₹5.0 Cr of borrowings against ₹128 Cr of equity in FY26, a debt-to-equity of 0.04. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹4.0 Cr to ₹5.0 Cr. Capital spending ran ₹37.0 Cr across the last 3 of those years.
FY26: borrowings of ₹5.0 Cr against equity of ₹128 Cr — a debt-to-equity of 0.04. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹4.0 Cr to ₹5.0 Cr while capital spending ran ₹37.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 1.4 points of Mold-Tek Technologies Ltd over 8 quarters, the biggest move on the register. That takes promoters to 50.5% of the company. Domestic institutions moved −1.2 points over the same window, to 0.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +1.4 points over 8 quarters to 50.5%; Domestic institutions: −1.2 points over 8 quarters to 0.5%; Foreign institutions: +0.0 points over 8 quarters to 0.2%.
Why the register moved: promoters drove it (+1.4 points), absorbed on the other side by domestic institutions (−1.2 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Mold-Tek Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Mold-Tek Technologies Ltd trades at 30.2× P/E, at the pricey end of its own range (83rd percentile). Its long-run median P/E is 20.6×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.2× is at the pricey end of its own range (83rd percentile), against a long-run median of 20.6× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 26 August 2026 price, Mold-Tek Technologies Ltd was paying for profit growth of about 19.1% a year. Profit itself has compounded 5.2% a year over the past 10 years. Today the market pays 30.2× P/E, the 83rd percentile of its own 10-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is far above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 26 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 18 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Mold-Tek Technologies Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +24.7% | +7.4% | +17.0% | +13.1% |
| Profit | −16.7% | −29.9% | +0.0% | +5.2% |
| EPS | −17.8% | −30.4% | −0.4% | +4.9% |
4-Factor Sector Score
57.9/100 — rank 2 of 18 in Infra - Construction & Contracting · 67% evidence confidence
Mold-Tek Technologies Ltd scores 57.9 out of 100 against the 18 companies it is compared with in Infra - Construction & Contracting, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 28 + 10.2 + 7.4 + 12.3 = 57.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Mold-Tek Technologies Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Berryl Employee Retention Contradiction · 6 August 2026. In May 2026, management stated that no Berryl employees had resigned after five months of ownership. In Aug 2026, management said that two of 38 employees had been lost, specifically from the design function, creating a direct contradiction about retention and the source of the design-team disruption.
🚨 Berryl Margin Outlook Fell Materially Below Earlier Target · 6 August 2026. In Feb 2026, management expected Berryl's EBITDA margin to reach 30%-35% within a year after outsourcing half of the work to India. In Aug 2026, management projected only approximately 8% EBITDA for the full year and described Berryl as around break-even, a material reduction in the expected contribution that affects the acquisition's valuation case.
MSA Revenue Potential and Scope Changed Without Reconciliation · 6 August 2026. The May 2026 call described the MSA as a Danieli Corus manpower-support mandate with a potential of approximately $0.5 million per year. In Aug 2026, management appeared to refer to the same previously discussed agreement but described it as a US power-transmission engagement and doubled the potential to $1 million per year, without explaining whether this was a new contract or a revised scope.
EBITDA Margin Guidance Materially Reduced · 14 May 2026. In the Feb 2026 call, management expressed strong confidence that EBITDA margins for FY27 would at least cross 20% and potentially return to 25%, citing Beryl contributions and MES downsizing as the primary drivers. In the May 2026 call, the FY27 EBITDA margin projection was cut to only 15%, a reduction of 5-10 percentage points with no direct explanation for why the prior 20-25% target is no longer achievable.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Cemindia Projects LtdCEMPRO | 59.4/100Mixed-positive evidence100% evidence | FADING | 24.1/35 Revenue 8.9% · PAT 47.2% · OPM change 1 pp 100% evidence | 17.3/25 ROCE 32.8% · OPM 10% 100% evidence | 2.5/20 P/E 36.1× · PEG 5.81 100% evidence | 15.5/20 RS sector 49.8% · RS bench 40.5% · 1Y 61.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.1 + 17.3 + 2.5 + 15.5 = 59.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Mold-Tek Technologies Ltdthis pageMOLDTECH | 57.9/100Mixed-positive evidence67% evidence | TURNING | 28.0/35 Revenue 48.7% · PAT 100% · OPM change 18.5 pp 95% evidence | 10.2/25 ROCE 9.5% · OPM 19.9% 76% evidence | 7.4/20 P/E 30.2× · PEG — 50% evidence | 12.3/20 RS sector — · RS bench 28.8% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 28 + 10.2 + 7.4 + 12.3 = 57.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Larsen & Toubro LtdLT | 56.9/100Mixed-positive evidence82% evidence | ASLEEP | 18.7/35 Revenue 9.8% · PAT 5.8% · OPM change -1 pp 95% evidence | 15.6/25 ROCE 14.6% · OPM 12% 76% evidence | 8.5/20 P/E 30.3× · PEG — 50% evidence | 14.1/20 RS sector 5.2% · RS bench -0.5% · 1Y 8.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 15.6 + 8.5 + 14.1 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4SPML Infra LtdSPMLINFRA | 52.5/100Mixed-positive evidence74% evidence | ASLEEP | 27.3/35 Revenue 37.8% · PAT 80.8% · OPM change 4.4 pp 95% evidence | 3.5/25 ROCE 6.8% · OPM 9% 95% evidence | 10.6/20 P/E 16.7× · PEG — 15% evidence | 11.1/20 RS sector 3.7% · RS bench -11.9% · 1Y -40.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 27.3 + 3.5 + 10.6 + 11.1 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Ramky Infrastructure LtdRAMKY | 51.1/100Mixed-positive evidence76% evidence | ASLEEP | 13.2/35 Revenue 4.6% · PAT 17.8% · OPM change -14 pp 95% evidence | 12.1/25 ROCE 13.7% · OPM 6% 76% evidence | 14.0/20 P/E 11.8× · PEG — 50% evidence | 11.8/20 RS sector 13.8% · RS bench -33% · 1Y -43.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.2 + 12.1 + 14 + 11.8 = 51.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 6Patel Engineering LtdPATELENG | 51.0/100Mixed-positive evidence100% evidence | ASLEEP | 14.7/35 Revenue -1.4% · PAT 4.7% · OPM change 1 pp 100% evidence | 15.3/25 ROCE 13.3% · OPM 14% 100% evidence | 15.0/20 P/E 6.5× · PEG 1.52 100% evidence | 6.0/20 RS sector -6.5% · RS bench -12.2% · 1Y -29.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 15.3 + 15 + 6 = 51 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7NBCC (India) LtdNBCC | 49.9/100Mixed-negative evidence82% evidence | ASLEEP | 18.5/35 Revenue 3.8% · PAT 30.9% · OPM change 2.4 pp 95% evidence | 17.8/25 ROCE 29.3% · OPM 7% 76% evidence | 10.1/20 P/E 32.5× · PEG — 50% evidence | 3.5/20 RS sector -11.2% · RS bench -16.4% · 1Y -22.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 17.8 + 10.1 + 3.5 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Likhitha Infrastructure LtdLIKHITHA | 46.9/100Mixed-negative evidence87% evidence | ASLEEP | 7.2/35 Revenue -18.8% · PAT -51.4% · OPM change -2.7 pp 95% evidence | 14.1/25 ROCE 13.7% · OPM 12.9% 95% evidence | 7.1/20 P/E 26.6× · PEG — 50% evidence | 18.5/20 RS sector 16.7% · RS bench 9.5% · 1Y -10.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 7.2 + 14.1 + 7.1 + 18.5 = 46.9 · Decision use: Price leads the evidence: RS versus the benchmark is 9.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Hazoor Multi Projects LtdHAZOOR | 46.2/100Mixed-negative evidence69% evidence | 13.6/35 Revenue -30.5% · PAT -34.1% · OPM change 70.1 pp 95% evidence | 13.4/25 ROCE 12% · OPM 84.5% 76% evidence | 10.4/20 P/E 17.9× · PEG — 15% evidence | 8.8/20 RS sector 1.7% · RS bench -34.6% · 1Y -53%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 13.6 + 13.4 + 10.4 + 8.8 = 46.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Hindustan Construction Company LtdHCC | 45.9/100Mixed-negative evidence93% evidence | ASLEEP | 5.8/35 Revenue -20.7% · PAT 0% · OPM change -5 pp 100% evidence | 15.4/25 ROCE 24.8% · OPM 11% 100% evidence | 11.4/20 P/E 42.1× · PEG 1.3 65% evidence | 13.3/20 RS sector 12.7% · RS bench 5.8% · 1Y -9.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 5.8 + 15.4 + 11.4 + 13.3 = 45.9 · Decision use: Price leads the evidence: RS versus the benchmark is 5.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11PNC Infratech LtdPNCINFRA | 44.4/100Mixed-negative evidence100% evidence | ASLEEP | 15.9/35 Revenue -6.5% · PAT 9.4% · OPM change 5 pp 100% evidence | 10.0/25 ROCE 8% · OPM 31% 100% evidence | 17.9/20 P/E 5.9× · PEG 0.17 100% evidence | 0.6/20 RS sector -34.2% · RS bench -38.3% · 1Y -54.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 10 + 17.9 + 0.6 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12IRB Infrastructure Developers LtdIRB | 44.3/100Mixed-negative evidence82% evidence | BASING | 15.7/35 Revenue -2.2% · PAT -80% · OPM change 9 pp 95% evidence | 10.7/25 ROCE 7.5% · OPM 54% 76% evidence | 10.2/20 P/E 22.7× · PEG — 50% evidence | 7.7/20 RS sector -5.1% · RS bench -10.3% · 1Y -13.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 10.7 + 10.2 + 7.7 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Simplex Infrastructures LtdSIMPLEXINF | 43.2/100Mixed-negative evidence81% evidence | ASLEEP | 24.5/35 Revenue 4.6% · PAT 80.8% · OPM change 3.9 pp 95% evidence | 4.4/25 ROCE 2.4% · OPM 7% 95% evidence | 5.6/20 P/E 44× · PEG — 50% evidence | 8.7/20 RS sector -19.8% · RS bench 5.1% · 1Y -14.9%6 of 10 weeks ahead 70% evidence |
| Exact sum: 24.5 + 4.4 + 5.6 + 8.7 = 43.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14H.G. Infra Engineering LtdHGINFRA | 40.3/100Mixed-negative evidence94% evidence | ASLEEP | 15.1/35 Revenue -3.1% · PAT -57.9% · OPM change 10 pp 100% evidence | 13.3/25 ROCE 11.3% · OPM 28% 100% evidence | 7.0/20 P/E 11.1× · PEG 3.17 100% evidence | 4.9/20 RS sector -27.7% · RS bench -30.7% · 1Y -54.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.1 + 13.3 + 7 + 4.9 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15KNR Constructions LtdKNRCON | 40.3/100Mixed-negative evidence82% evidence | ASLEEP | 4.3/35 Revenue -39% · PAT -58.8% · OPM change -14 pp 95% evidence | 11.7/25 ROCE 10.4% · OPM 16% 76% evidence | 13.4/20 P/E 10.3× · PEG — 50% evidence | 10.9/20 RS sector -4.9% · RS bench -10.8% · 1Y -36.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 4.3 + 11.7 + 13.4 + 10.9 = 40.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 16Rail Vikas Nigam LtdRVNL | 39.1/100Mixed-negative evidence87% evidence | BASING | 16.1/35 Revenue 5.4% · PAT -24.5% · OPM change 2.9 pp 100% evidence | 7.0/25 ROCE 10.8% · OPM 4.3% 100% evidence | 4.5/20 P/E 49.7× · PEG 5.08 65% evidence | 11.5/20 RS sector 6% · RS bench -23.8% · 1Y -36.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 7 + 4.5 + 11.5 = 39.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Vishnu Prakash R Punglia LtdVPRPL | 30.3/100Thin evidence · provisional54% evidence | 9.4/35 Revenue -22.6% · PAT -80% · OPM change -18 pp 53% evidence | 9.4/25 ROCE 11.4% · OPM -7% 71% evidence | 8.5/20 P/E 59.9× · PEG — 15% evidence | 3.0/20 RS sector -56.9% · RS bench -67.1% · 1Y -72.4%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 9.4 + 9.4 + 8.5 + 3 = 30.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Giriraj Civil Developers LtdGIRIRAJ | 51.6/100Thin evidence · provisional44% evidence | 21.2/35 Revenue 100% · PAT 100% · OPM change 2 pp 27% evidence | 15.0/25 ROCE 20.1% · OPM 8% 71% evidence | 10.3/20 P/E 21.1× · PEG — 15% evidence | 5.1/20 RS sector -32.2% · RS bench -12.3% · 1Y -38.9%4 of 11 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 21.2 + 15 + 10.3 + 5.1 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Mold-Tek Technologies Ltd's share price today?
Mold-Tek Technologies Ltd trades at ₹193. The company is valued at ₹555 Cr. The stock sits at 81% of its 52-week range of ₹125–₹209, +24.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 18 September 2026.
What were Mold-Tek Technologies Ltd's latest quarterly results?
Mold-Tek Technologies Ltd reported revenue of ₹59.5 Cr and net profit of ₹9.0 Cr for the Jun 26 quarter. Revenue rose 78.9% and profit rose 1,223.5% year on year. Earnings per share were ₹3.12. The operating margin was 19.9%, 18.5 pp higher than a year earlier. — as of 18 September 2026.
What is Mold-Tek Technologies Ltd's revenue?
Mold-Tek Technologies Ltd reported revenue of ₹59.5 Cr in the Jun 26 quarter, +78.9% year on year. For the full FY26 fiscal year, revenue was ₹182 Cr (+24.7%). Over the last 10 years revenue compounded at 13.1% a year. — as of 18 September 2026.
What is Mold-Tek Technologies Ltd's profit?
Mold-Tek Technologies Ltd earned ₹9.0 Cr of net profit in the Jun 26 quarter, +1,223.5% year on year. Full-year FY26 profit was ₹10.0 Cr. The operating margin ran 19.9% in the latest quarter. — as of 18 September 2026.
What is Mold-Tek Technologies Ltd's market cap?
Mold-Tek Technologies Ltd's market capitalisation is ₹555 Cr at a share price of ₹193. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 18 September 2026.
What is Mold-Tek Technologies Ltd's P/E ratio?
Mold-Tek Technologies Ltd trades at a P/E of 30.2×, at the 83rd percentile of its own 10-year range, against a long-run median of 20.6×. This is a comparison with the stock's own history, not a value call — as of 18 September 2026.
Does Mold-Tek Technologies Ltd pay a dividend?
Yes — Mold-Tek Technologies Ltd's dividend payout was 57% of profit in FY26, and it recorded a payout in each of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 18 September 2026.
Is Mold-Tek Technologies Ltd overvalued?
On its own history, Mold-Tek Technologies Ltd looks expensive: its P/E of 30.2× sits at the 83rd percentile of its 10-year range (long-run median 20.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 18 September 2026.
Is Mold-Tek Technologies Ltd growing?
Yes — Mold-Tek Technologies Ltd is growing: latest-quarter revenue +78.9% year on year, profit +1,223.5%, and the margin +18.5 pp at 19.9%. The 10-year compound rates are 13.1% (revenue) and 5.2% (profit). The earnings engine currently reads: improving — as of 18 September 2026.
How is Mold-Tek Technologies Ltd performing?
Mold-Tek Technologies Ltd is in a confirmed uptrend, 5 weeks in. Its latest quarter's revenue rose 78.9% and profit rose 1,223.5% year on year. This describes what the data did, not a rating. — as of 18 September 2026.
Is Mold-Tek Technologies Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +24.5% versus its 200-day average and at 81% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 18 September 2026.
Will Mold-Tek Technologies Ltd's share price go up?
This page publishes no price forecast for Mold-Tek Technologies Ltd. What it measures instead: the share price is ₹193, the price is in a confirmed uptrend 5 weeks in. Its P/E of 30.2× sits at the 83rd percentile of its own 10-year range. — as of 18 September 2026.
Who owns Mold-Tek Technologies Ltd?
Promoters hold 50.5% of Mold-Tek Technologies Ltd, foreign institutions 0.2%, domestic institutions 0.5% and the public 48.9% (latest quarter). The biggest move on the register over the last two years: Promoters added 1.4 points over 8 quarters. — as of 18 September 2026.
Does Mold-Tek Technologies Ltd have too much debt?
No — Mold-Tek Technologies Ltd's debt-to-equity is 0.04, and operating profit covers the interest bill 12×. FY26 borrowings were ₹5.0 Cr against equity of ₹128 Cr. The returns on this page are earned, not borrowed — as of 18 September 2026.
What is Mold-Tek Technologies Ltd's capex?
Mold-Tek Technologies Ltd spent ₹37.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹25.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 18 September 2026.
What is Mold-Tek Technologies Ltd's cash flow?
Mold-Tek Technologies Ltd generated ₹15.0 Cr of operating cash flow in FY26 and ₹−10.0 Cr of free cash flow after ₹25.0 Cr of capital spending. Reported profit that year was ₹10.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 18 September 2026.
Is Mold-Tek Technologies Ltd's profit real cash?
Yes — over the last 3 fiscal years, 144% of Mold-Tek Technologies Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹15.0 Cr against reported profit of ₹10.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 18 September 2026.
Where is Mold-Tek Technologies Ltd in its business cycle?
Mold-Tek Technologies Ltd's FY26 operating margin was 6.0%, against a 12-year band of 6.0%–29.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 19.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 18 September 2026.
What growth does Mold-Tek Technologies Ltd's price assume?
At its price on 26 August 2026, Mold-Tek Technologies Ltd was priced for profit growth of about 19.1% a year. Profit itself has compounded 5.2% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 18 September 2026.
What could break the Mold-Tek Technologies Ltd story?
The sharpest disagreement: the engine is strong, but at the 83rd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 18 September 2026.
Is Mold-Tek Technologies Ltd a stock worth studying right now?
This is not investment advice. The machine read: Mold-Tek Technologies Ltd is strength at full price. The numbers are improving — and a P/E at the 83rd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 18 September 2026.
Not SEBI Registered !! Not Investment advice !!